Close Menu

NEW YORK — French diagnostics firm Novacyt said on Thursday that it has received CE marking for its Winterplex PCR-based respiratory panel, which can differentiate SARS-CoV-2 from common winter infections.

Winterplex includes two gene targets specific to SARS-CoV-2, as well as gene targets for influenza A and B and respiratory syncytial virus. According to Novacyt, Winterplex has demonstrated 100 percent specificity and 96 percent to 100 percent sensitivity across the panel in clinical testing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.